Radiotherapy of the Pancreas: State of the Art in 2012

  • F. Mornex
  • M. Hatime
  • S. Touch
  • B. Elmorabit
  • G. Pigne
  • C. Enachescu
  • O. Diaz
  • Y. Elkhoti
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 196)


Pancreatic adenocarcinoma (PA) is a rare tumor; it represents 2–3 % of all new cancer cases in Europe and USA, and 95 % of malignant pancreatic tumors (Parkin et al. 2001). PA is an aggressive disease with a poor prognosis, one-year survival rate of 25 % and a five-year survival rate of less than 5 % (Evans et al. 2001). PA is among the top five causes of cancer-related death in adults in most industrialized countries, with over 70,000 deaths per year in Europe and the USA (Fernandez et al. 1994; Bramhall et al. 1995; Bramhall et al. 1998; Parkin et al. 2001; Jemal et al. 2002).


Epidermal Growth Factor Receptor Pancreatic Cancer Pancreatic Adenocarcinoma Modulate Intensity Radiotherapy Stereotactic Body Radiation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alfieri S, Morganti AG, Di Giorgio A et al (2001) Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch Surg 136:343–347PubMedCrossRefGoogle Scholar
  2. Baumel H, Huguier M, Manderscheid JC et al (1994) Results of resection for cancer of the exocrine pancreas: a study from the French association of surgery. Br J Surg 81:102–110PubMedCrossRefGoogle Scholar
  3. Ben-Josef E, Griffith K, Francis IR et al (2009) Phase I radiation dose –escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDRG) for unresecatable pancreatic cancer. J Clin Oncol 27:a4602CrossRefGoogle Scholar
  4. Ben-Josef E, Shields AF, Vaishampayan U et al (2004) Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59:454–459PubMedCrossRefGoogle Scholar
  5. Bichenbach KA, Gonen M,Tang LH et al. (2011) Down staging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Annal surgical oncol. doi: 10.124/s10434-011-2156-7Google Scholar
  6. Bouchard M, Amos RA, Briere TM et al (2009) Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol 92:238–243PubMedCrossRefGoogle Scholar
  7. Bramhall SR, Allum WH, Jones AG et al (1995) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82:111–115PubMedCrossRefGoogle Scholar
  8. Bramhall SR, Dunn J, Neoptolemos JP et al. (1998) Epidemiology of pancreatic cancer. In: Carr-Locke (ed); the pancreas, Blackwell Scientific, Boston pp 889–906Google Scholar
  9. Chang BW, Saif MW (2008) Stereotactic body radiation therapy (SBRT) in Pancreatic Cancer: is it ready for prime time. JOP. J Pancreas (Online) 9(6):676–682Google Scholar
  10. Ceha HM, Van Tienhoven G, Gouma DJ et al (2000) Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89:2222–2229PubMedCrossRefGoogle Scholar
  11. Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing initial chemoradiotherapy (intermittent cisplatine and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. Ann Oncol 19:1592–1599PubMedCrossRefGoogle Scholar
  12. Crane CH, Antolak JA, Rosen II et al (2001) Phase I study of concomitant gemcitabine and IMRT for patient with unresecable adenocarcinoma of the pancreatic head. Int J Gastrointest cancer 30:123–132PubMedCrossRefGoogle Scholar
  13. Chang DT, Schellenberg D, Shen J et al. (2008) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009. doi:  10.1002/cncr.24059
  14. Ducreux M, Boige V, Goéré D et al (2007) Pancreatic cancer: from pathogenesis to cure. Best Pract Res Clin Gastroenterol 21(6):997–1014PubMedCrossRefGoogle Scholar
  15. Edis AJ, Kiernan PD, Taylor WF (1980) Attempted curative resection of ductal carcinoma of the pancreas. Review of Mayo clinic experience, 1951–1975. Mayo Clin Proc 55:531–536PubMedGoogle Scholar
  16. Evans DB, Abbruzzese JL, Willett CG et al. (2001) Cancer of the pancreas. Principles and practice of oncology. In: Hellman S, Rosenberg SA (eds), Lippincott Williams and Wilkins, Philadelphia 1126–1161Google Scholar
  17. Evans DB, Varadhachary GR, Crane CH et al (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496–3502PubMedCrossRefGoogle Scholar
  18. Fernandez E, La Vecchia C, Porta M et al (1994) Trends in pancreatic cancer mortality in Europe, 1955–1989. Int J Cancer 57:786–792PubMedCrossRefGoogle Scholar
  19. Gillen S, Schuster T, Meyer Zum Büschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4): e1000267Google Scholar
  20. Gillmore R, Laurence V, Raouf S et al (2010) Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clin Oncol (R Coll Radiol) 22(7): 564–569CrossRefGoogle Scholar
  21. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  22. Griffin JF, Smalley SR, Jewell W et al (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56–61PubMedCrossRefGoogle Scholar
  23. Haller DG (2003) Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 56:16–23PubMedCrossRefGoogle Scholar
  24. Hidalgo M (2010) Pancreatic cancer. N E J Med 362:1605–1617CrossRefGoogle Scholar
  25. Hoffman JP, Lipsitz S, Pisansky T et al (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an eastern cooperative oncology group study. J Clin Oncol 16:317–323PubMedGoogle Scholar
  26. Hoffman JP, Weese JL, Solin LJ et al (1995) A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169:71–77PubMedCrossRefGoogle Scholar
  27. Hsu CC, Herman JM, Corsini MM et al (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins hospital-mayo clinic collaborative study. Ann Surg Oncol 17:981–990PubMedCrossRefGoogle Scholar
  28. Huang J, M.robertson J, Margolis J and al (2011) Long-term results of full-dose gemcitabine with radiation therapy compared TO 5-FLUOROURACIL radiation therapy for locally advanced pancreas cancer. doi: 10.1016/j.radonc.2011.05.038
  29. Janes RH, Niederhuber JE, Chmiel JS et al (1996) National patterns of care for pancreatic cancer. Results of a survey by the commission on cancer. Ann Surg 223:261–272PubMedCrossRefGoogle Scholar
  30. Jemal A, Thomas A, Murray T et al (2002) Cancer statistics. CA Cancer J Clin 52:23–47PubMedCrossRefGoogle Scholar
  31. Johnstone PA, Sindelar WF (1993) Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of a clinical trial. Int J Radiat Oncol Biol Phys 27:831–834PubMedCrossRefGoogle Scholar
  32. Johung K, Saif MW, Chang BW (2012) Treatment of locallyadvanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys 82(2):508–518PubMedCrossRefGoogle Scholar
  33. Kindler HL, Niedzwiecki D, Hollis D, et al (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB) 80303. In Proceedings of the GI ASCO symposium, abstract no 108.
  34. Klinkenbijl HL, Jeekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782PubMedCrossRefGoogle Scholar
  35. Krempien R, Munter MW, Timke C et al. (2007) Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial [PARC-Study ISRCTN56652283]. Proc Am Soc Clin Oncol, 25:4573Google Scholar
  36. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C (2011) A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 15(11):2059–2069. doi: 10.1007/s11605-011-1659 PubMedCrossRefGoogle Scholar
  37. Le Scodan R, Mornex F, Girard N et al (2009) Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 20(8): 1387–1396PubMedCrossRefGoogle Scholar
  38. Lee JH, Whittington R, Williams NN et al (2000) Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47:945–953PubMedCrossRefGoogle Scholar
  39. Mahadevan A, Jain S, Goldstein M et al (2010) Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiation Oncology Biol Phys 78(3):735–742CrossRefGoogle Scholar
  40. Manabe T, Ohshio G, Baba N et al (1989) Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 64:1132–1137PubMedCrossRefGoogle Scholar
  41. Mehta VK, Fisher GA, Ford JM et al (2000) Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 48:1483–1487PubMedCrossRefGoogle Scholar
  42. Milano MT, Chmura SJ, Garofalo MC et al (2004) Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59:445–453PubMedCrossRefGoogle Scholar
  43. Moertel CG, Childs DS, Reitemeier RJ et al (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867PubMedCrossRefGoogle Scholar
  44. Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Gastrointest Tumor Study Group Cancer 48:1705–1710Google Scholar
  45. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 25:1960–1966PubMedCrossRefGoogle Scholar
  46. Mori S, Hara R, Yanagi T et al (2009) Four-dimensional measurement of intrafractional respiratory motion of pancreatic tumours using a 256 multi-slice CT scanner. Radiother Oncol 92:231–237PubMedCrossRefGoogle Scholar
  47. Mornex F, Girard N, Scoazec JY et al (2006) Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 phase II trial. Int J Radiat Oncol Biol Phys 65(5): 1471–1478PubMedCrossRefGoogle Scholar
  48. Neoptolemos JP, Stocken DD, Friess H (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210PubMedCrossRefGoogle Scholar
  49. Pan T, Lee TY, Rietzel E et al (2004) 4D-CT imaging of a volume influenced by Respiratory motion on multi-slice CT. Med Phys 31:333–340PubMedCrossRefGoogle Scholar
  50. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl. 8):S4–S66PubMedCrossRefGoogle Scholar
  51. Philip PA, Benedetti C, Fenoglio-Preiser Cet al (2007). Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S025 study. Proc Am Soc Clin Oncol, 25:[LBA4509]Google Scholar
  52. Rietzel E, Chen GT, Choi NC et al (2005) Four-dimensional image-based treatment planning target volume segmentation and dose calculation in the presence of respiratory motion. Int J Radiat Oncol Biol Phys 61:535–555CrossRefGoogle Scholar
  53. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. (2008) Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299:1019–1026. [PMID18319412]Google Scholar
  54. Roy R, Maraveyas A (2010) Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist 15:259–269PubMedCrossRefGoogle Scholar
  55. Schellenberg D, Kim J, Christman-Skieller C et al (2011) Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 81(1):181–188PubMedCrossRefGoogle Scholar
  56. Sohn TA, Lillemoe KD, Cameron JL et al (1999) Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg 229:393–400PubMedCrossRefGoogle Scholar
  57. Stessin AM, Meyer JE, Sherr DL (2008) Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 72(4): 1128–1133Google Scholar
  58. Sultana A, Tudur Smith C, Cunningham D et al (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreaticcancer using radiation/combined modality therapy. Br J Cancer 96(8):1183–1190Google Scholar
  59. Talamonti MS, Catalano PJ, Vaughn DJ et al (2000) Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18:3384–3389PubMedGoogle Scholar
  60. Van Laethem JL, Demols A, Gay F et al (2003) Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys 56:974–980PubMedCrossRefGoogle Scholar
  61. Van Laethem JL, Hammel P, Mornex F, Azria D, et al. (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. J Clin Oncol 2010. doi:  10.1200/JCO.2010.30.3446
  62. Van Tienhoven JL, Gouma J, Richel D (2011) Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol 3(1) 27_33Google Scholar
  63. Westerdahl J, Andren-Sandberg A, Ihse I (1993) Recurrence of exocrine pancreatic cancer—local or hepatic. Hepatogastroenterology 40:384–387PubMedGoogle Scholar
  64. Wey JS, Fan F, Gray MJ et al (2005) Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104:427–438PubMedCrossRefGoogle Scholar
  65. Willett CG, Kozin SV, Duda DG et al (2006) Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33:S35–S40PubMedCrossRefGoogle Scholar
  66. Willett CG, Lewandrowski K, Warshaw AL et al (1993) Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 217:144–148Google Scholar
  67. Willett CG, Safran H, Abrams RA et al (2003) Clinical research in pancreatic cancer: the radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys 56:31–37PubMedCrossRefGoogle Scholar
  68. Xi M, Liu MZ, Deng XW, Zhang L, Huang XY, Liu H et al (2007) Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol 8:272–278CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • F. Mornex
    • 1
  • M. Hatime
    • 1
  • S. Touch
    • 1
  • B. Elmorabit
    • 1
  • G. Pigne
    • 1
  • C. Enachescu
    • 1
  • O. Diaz
    • 1
  • Y. Elkhoti
    • 1
  1. 1.Radiation Oncology DepartmentCentre Hospitalier Lyon Sud, Université Claude BernardLyonFrance

Personalised recommendations